New Vaccine Partnership With GSK Could Act As Lifeline For Chinese Biotech Firm Neptunus In Troubled Financial Seas
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline provides leading-edge vaccine technology and equipment, along with an injection of cash totaling almost $30 million, while Neptunus contributes its production facilities and access to the Chinese market.